Stéphanie De Simoni

Author

Stéphanie De Simoni

Chinese University of Hong Kong

Also Known As

Annalise Serra Melechì, Francesca Simeoni, S De Simoni, Sofia Simoni, Stephanie De Simoni, Stéphanie De Simoni

Publications

298

Citations

H-Index

Concepts

All Affiliations

Chinese University of Hong Kong University of Genoa Institut Curie Karolinska Institutet GlaxoSmithKline (India)

About

Stéphanie De Simoni is an author at Chinese University of Hong Kong specializing in medicine, biochemistry, and mitochondrial function.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	147
2	Biochemistry	2	2	147
3	Cell Biology	2	2	147
4	Natural Sciences	1	1	56
5	Molecular Biology	1	1	56

Stéphanie De Simoni

Publications

295

Citations

H-Index

Page 1

	Year	Citations
Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+ Stéphanie De Simoni, Julie Goemaere, Bernard Knoops Neuroscience Letters Peroxiredoxin 3MitophagyMolecular NeuroscienceMitochondrial PeroxiredoxinsMitochondrial Function	2008	91
Mitochondrial peroxiredoxin‐5 as potential modulator of mitochondria‐<scp>ER</scp> crosstalk in <scp>MPP</scp><sup>+</sup>‐induced cell death Stéphanie De Simoni, Dominique Linard, Emmanuel Hermans, Journal of Neurochemistry Mitochondrial DysfunctionApoptosisCell DeathMolecular BiologyMitochondrial Biology	2012	56
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial Ting Fan Leung, Anthony Pak‐Yin Liu, Fong Seng Lim, Human Vaccines & Immunotherapeutics	2015	49
Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years Thanyawee Puthanakit, Li‐Min Huang, Cheng‐Hsun Chiu, The Journal of Infectious Diseases	2016	46
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial Ting Fan Leung, Anthony Pak‐Yin Liu, Fong Seng Lim, Vaccine	2017	27
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial Li‐Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, The Journal of Infectious Diseases	2017	26

Page 1